Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2008, for Cactus Ventures, Inc. (Note: The input metadata referenced "Actinium Pharmaceuticals," but the filing text explicitly identifies the registrant as Cactus Ventures, Inc.). The Company is a Nevada corporation operating as a shell entity with no active business operations. Its primary objective is to seek a merger or acquisition with a target company to provide a path to public reporting status. The Company has no employees, no owned property, and relies on the President's residence for office space.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2008 | Six Months Ended June 30, 2007 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(20,301) | $(3,810) |
| Operating Expenses | $18,009 | $2,840 |
| Interest Expense | $2,292 | $970 |
| Cash and Cash Equivalents (Ending) | $2,266 | $466 |
| Total Assets | $2,266 | $2,314 |
| Total Liabilities | $65,285 | $45,032 |
| Shareholders' Deficit | $(63,019) | $(42,717) |
| Working Capital | $(21,022) | $(6,759) |
Note: The filing does not provide data on gross margins or operating margins as there is no revenue.
Material Changes vs. Prior Period
- Increased Losses: Net loss increased significantly from $(3,810) in the prior year period to $(20,301), driven primarily by a rise in professional fees and other operating costs.
- Expense Growth: Total operating expenses jumped from $2,840 to $18,009. Professional fees specifically increased from $2,840 to $10,770.
- Liability Accumulation: Total liabilities grew by approximately 45% to $65,285. This includes a rise in accounts payable to $9,548, accrued legal fees to $7,770, and notes payable to related parties to $41,997.
- Cash Flow: The Company generated a net cash outflow from operating activities of $(6,086), partially offset by $6,038 in financing from related party notes, resulting in a negligible decrease in cash on hand.
Outlook, Risks, and Contingencies
- Going Concern: The filing explicitly states that the Company's net loss, negative working capital, and stockholders' deficit raise substantial doubt about its ability to continue as a going concern. Continued operations depend entirely on raising additional funds and successfully implementing a business plan (merger/acquisition).
- Financing Needs: The Company has no material commitments but lacks the liquidity to meet current needs. It anticipates receiving contributions from shareholders but has no binding agreements. Future capital may be raised via stock sales or loans from officers/directors.
- Business Strategy Risks: There is no assurance the Company will locate a suitable target for merger. Management has limited time to devote to the business, and the sole officer has no written employment agreement.
- Market Risks: The stock is subject to "Penny Stock" rules, which impose significant restrictions on broker-dealers and may severely limit liquidity and the ability of investors to resell shares.
Investor Verification Checklist
- Identity Confirmation: Verify that the filing pertains to Cactus Ventures, Inc. and not Actinium Pharmaceuticals, as the metadata and filing text differ.
- Related Party Debt: Confirm the terms and repayment status of the $41,997 in notes payable to related parties.
- Capital Sufficiency: Assess the likelihood of obtaining the necessary shareholder contributions to cover the $21,022 working capital deficit and ongoing operating expenses.
- Merger Progress: Investigate if any specific target companies are currently under negotiation, as the filing states no assurances exist regarding a future business combination.
- Liquidity Constraints: Evaluate the impact of Penny Stock regulations on the potential exit strategy for current shareholders.